FibroBiologics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
FibroBiologics, Inc. (FBLG) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.04 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-07-31
- FibroBiologics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $0.85, a 0.00% change year-over-year.
- FibroBiologics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $0.85, a 92.12% decline year-over-year.
- FibroBiologics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $10.79.
- FibroBiologics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $0.87, a 77.23% decline from fiscal 2024.
- FibroBiologics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $3.82, a 112.22% increase from fiscal 2023.
- FibroBiologics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $1.80, a 31.82% decline from fiscal 2022.
- FibroBiologics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $2.64.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.04 10-Q · filed 2026-07-31 | |||
| 2026-03-31 | $0.85 10-Q · filed 2026-04-30 | |||
| 2025-12-31 | $0.87 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $0.87 10-Q · filed 2025-10-31 | |||
| 2025-06-30 | $0.87 10-Q · filed 2026-07-31 | |||
| 2025-03-31 | $0.85 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | $3.82 10-K · filed 2026-02-24 | |||
| 2024-09-30 | $9.70 10-Q · filed 2025-10-31 | |||
| 2024-06-30 | $10.63 10-Q · filed 2025-07-31 | |||
| 2024-03-31 | $10.79 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $1.80 10-K · filed 2025-03-31 | |||
| 2022-12-31 | $2.64 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 |